Second-Line Medications for Neonatal Opioid Withdrawal Syndrome/Neonatal Abstinence Syndrome

Area of Science:

• Neonatal care
• Pharmacology
• Pediatrics

Background:

• Nonpharmacologic management is the primary approach for infants with neonatal opioid withdrawal syndrome (NOWS) and neonatal abstinence syndrome (NAS).
• Opioids like morphine are common first-line pharmacologic treatments, with methadone and buprenorphine also utilized.
• Some infants require additional pharmacologic intervention when standard treatments are inadequate.

Purpose of the Study:

• To describe phenobarbital and clonidine as commonly prescribed second-line agents for NOWS/NAS.
• To provide an overview of these agents in managing refractory neonatal withdrawal symptoms.

Main Methods:

• This content column reviews existing literature and clinical practices regarding second-line pharmacologic agents for NOWS/NAS.
• Focuses on phenobarbital and clonidine as commonly used options.

Main Results:

• Phenobarbital and clonidine are frequently employed when first-line opioid therapy and nonpharmacologic strategies fail to manage NOWS/NAS symptoms.
• These agents offer alternative or adjunctive treatment options for healthcare providers.

Conclusions:

• Phenobarbital and clonidine are important second-line pharmacologic options for managing infants with NOWS/NAS who do not respond adequately to first-line treatments.
• Understanding these agents is crucial for optimizing care for affected neonates.